SEC Filing Summary for BioAge Labs, Inc. - Form 4 Filing

This Form 4 filing details a stock option grant to Patrick G. Enright, a director at BioAge Labs, Inc. On June 10, 2026, Mr. Enright was granted 22,000 stock options with a right-to-buy nature. The transaction code is 'A' for acquisition, and the shares were acquired at a price of $0.00 per share. These options are exercisable into 22,000 shares of BioAge Labs, Inc. Common Stock. The option award vests on the earlier of the next annual meeting or the one-year anniversary of the grant date, contingent upon continued service. The exercise price for these options is $15.48 per share, and they expire on June 9, 2036. Following this transaction, Mr. Enright owns 22,000 shares of common stock.